Merck
CN
  • Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different?

Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different?

La Radiologia medica (2013-12-04)
Tommaso Vincenzo Bartolotta, Adele Taibbi, Giuseppe Brancatelli, Domenica Matranga, Marisa Tumbarello, Massimo Midiri, Roberto Lagalla
摘要

This study was undertaken to compare the imaging findings of focal nodular hyperplasia (FNH) in men and women, as seen on multidetector computed tomography (MDCT), magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS). Two radiologists reviewed 195 imaging studies (17 MDCT, 81 MRI and 97 CEUS examinations) pertaining to 111 FNHs (mean size 3 cm) in 91 patients (mean age 39 years). For each lesion, the readers assessed size, location, echogenicity, attenuation, or signal intensity in comparison with adjacent liver parenchyma on both unenhanced and postcontrast images. Eighty-nine FNHs (mean size 3.1 cm) were observed in 73 women (mean age 37.9 years) and 22 FNHs (mean size 2.7 cm) in 18 men (mean age 41.2 years). No statistically significant differences were found between men and women in terms of age, FNH lesions per patient (1.22 and 1.21, respectively), size, baseline and enhancement pattern on MRI, CEUS and MDCT (p < 0.05). A central scar in FNHs was depicted in 4/18 (22.2%) men and 16/63 (25.4%) women on MRI (p < 0.05), and in 1/2 (50%) men and 7/15 (46.7%) women on MDCT (p < 0.05), whereas a spoke-wheel pattern, central scar, and/or feeding vessel were seen in 5/17 (29.4%) men and 22/80 (27.5%) women on CEUS (p < 0.05). Our results did not show any differences in imaging features, age of occurrence and size of FNH between men and women.

材料
货号
品牌
产品描述

Sigma-Aldrich
N -甲基- D -葡胺, 99.0-100.5% (titration)
Sigma-Aldrich
N -甲基- D -葡胺, ReagentPlus®, ≥99.0% (T)
Sigma-Aldrich
葡甲胺, 99.0-100.5% dry basis, meets USP testing specifications
Supelco
胆影葡胺, Pharmaceutical Secondary Standard; Certified Reference Material
胆影葡胺, European Pharmacopoeia (EP) Reference Standard